In High Risk Patients, Canagliflozin Reduces Risk of Cardiovascular Death and Heart Failure Hospitalization
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Circulation 2018 Mar 11;[EPub Ahead of Print], K Rådholm, G Figtree, V Perkovic, SD Solomon, KW Mahaffey, D de Zeeuw, G Fulcher, TD Barrett, W Shaw, M Desai, DR Matthews, B NealFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.